Application
Development Status
IP Status
Commercial Offerings
Opportunity
There is a growing burden of bacterial & fungal infections worldwide and accurate diagnosis remains a cornerstone to providing effective treatment. The development of optical molecular imaging smartprobes to detect bacteria or fungi in vivo in situ at the bedside would provide a paradigm-changing technology to many aspects of infectious medicine. BAC ONE has been shown to detect bacteria and fungi in a number of diseases including pneumonia, cystic fibrosis and in corneal scrapes from patients with suspected microbial keratitis.
With broad patent protection in the US, there is also the opportunity to further develop these tri-branched dendrimer probes for your own applications.
Dendrimers have a range of potential applications in biology and medicine, including drug delivery, imaging, and gene therapy. In drug delivery, dendrimers can be used to target specific cells or tissues, increasing the efficiency and reducing the side effects of drugs. In imaging, dendrimers can be used as contrast agents to enhance the visibility of certain structures in the body. In gene therapy, dendrimers can be used to deliver genetic material to cells to correct genetic disorders. Dendrimers also have potential applications in materials science, electronics, and nanotechnology.
Technology Overview
BAC ONE is a modified tri-branched dendrimer based on an antimicrobial peptide (Ubiquicidin) scaffold, with each dendrimer coupled to an NBD fluorophore via a PEG linker.
NBD is an environmentally sensitive fluorophore, with excitation at 465nm and peak emission at 540nm. Its environmentally sensitive composition means its fluorescence will increase in the presence of a hydrophobic environment and remain optically silent out with these conditions. As the apolar bacterial/fungal membrane is a hydrophobic environment, the fluorescence signal will increase in the membrane and allow microbial identification.
In vitro assays have confirmed BAC ONE labels a range of bacterial strains including S. aureus, K. pneumoniae, P. aeruginosa, E. coli and H. influenzae, amongst others, as well as filamentous fungi Aspergillus spp and Fusarium spp. BAC ONE does not label mammalian cells and does not result in any membrane toxicity or architectural changes. Furthermore, studies have shown that BAC ONE can detect colonised bacteria in situ in pulmonary segments of ventilated ovine lungs and in whole explant cystic fibrosis human lungs. Bac One is also able to detect bacterial and fungal pathogens collected directly from the cornea of microbial keratitis patients, with equivalent or better sensitivity and specificity than current gold-standard diagnostic techniques.
Benefits
Publications
Gunasekaran, R., Lalitha, P., Megia-Fernandez, A., Bradley, M., Williams, R. L., Dhaliwal, K., ... & Mills, B. (2020). Exploratory use of fluorescent SmartProbes for the rapid detection of microbial isolates causing corneal ulcer. American journal of ophthalmology, 219, 341-350.
Akram, A. R., Avlonitis, N., Scholefield, E., Vendrell, M., McDonald, N., Aslam, T., ... & Dhaliwal, K. (2019). Enhanced avidity from a multivalent fluorescent antimicrobial peptide enables pathogen detection in a human lung model. Scientific reports, 9(1), 1-10.
Akram, A. R., Avlonitis, N., Lilienkampf, A., Perez-Lopez, A. M., McDonald, N., Chankeshwara, S. V., ... & Dhaliwal, K. (2015). A labelled-ubiquicidin antimicrobial peptide for immediate in situ optical detection of live bacteria in human alveolar lung tissue. Chemical Science, 6(12), 6971-6979.
Technology Transfer Manager
Edinburgh Innovations Ltd
The University of Edinburgh